Authors Keywords: endometrial carcinoma, molecular era, low- to middle-income countries Abstract

The incidence of endometrial carcinoma (EC) has seen a steady increase globally over the years. According to the Cancer Association of South Africa (CANSA), EC is the fourth most common carcinoma in women. The publication of the International Federation of Gynecology and Obstetrics (FIGO) 2023 staging for the management of EC has incorporated molecular EC subtyping in addition to commonly used histopathological diagnosis. The four molecular subtypes of EC defined by The Cancer Genome Atlas (TCGA) research group have been renamed: 1) POLEmut (POLE ultramutated), 2) p53abn (p53-abnormal, copy number high), 3) MMRd (mismatch repair deficient, microsatellite instability hypermutated), and 4) NSMP (no specific molecular profile, copy number low). The molecular profiling of EC by TCGA used whole exome sequencing with determination of somatic copy number alterations (SCNA) on multiple platforms, which may prove costly in low- to middle-income countries (LMIC). The Proactive Molecular Risk Classifier of Endometrial Cancer (ProMisE) aims to validate TCGA results and investigate the correlation between the traditional clinicopathological prognostic features using a simple decision tree focused on immunohistochemistry and simple molecular testing. In a LMIC healthcare facility, the two molecular subtypes that can be tested using surrogates in immunohistochemical stains are p53 and MMRd, MLH1, PMS2, MSH2, and MSH6. There is no surrogate at present to test for POLE mutation; however, there is QPOLE – a low-cost quantitative multiplex polymerase chain reaction (PCR) that can detect the 11 most common and pathogenic POLE mutations. The use of a flow diagram in the daily clinical practice of patients with EC should be considered in LMIC. Future translational research in determining the cost-effectiveness of preoperative molecular pathology testing for treatment planning and risk stratification of patients is needed in resource-limited settings.

Author Biographies

J Lunn, University of Cape Town

Division of Anatomical Pathology, Department of Pathology, University of Cape Town and National Health Laboratory Service, South Africa

NH Mbatani, University of Cape Town

Department of Obstetrics and Gynaecology, University of Cape Town and Department of Obstetrics and Gynaecology, Groote Schuur Hospital, Western Cape Department of Health, South Africa

MJ Chokoe Maluleke, University of Cape Town

Division of Anatomical Pathology, Department of Pathology, University of Cape Town and National Health Laboratory Service, South Africa

Issue Section

Review Articles

License By submitting manuscripts to SAJGO, authors of original articles are assigning copyright to the South African Society of Gynaecologic Oncology (SASGO). Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJGO for educational and research purposes without obtaining permission.